DCC-2618

Ref. 3D-FD103402

Informations sur le produit

• Nom: DCC-2618
• Marque: Biosynth
• Description: DCC-2618 is a zirconium oxide-based compound that binds to the ATP binding site of the Bcr-Abl kinase domain. The compound inhibits the phosphorylation of tyrosine residues in proteins on which it has been targeted, leading to cell death. DCC-2618 is an orally bioavailable drug that is well tolerated by patients. It is a potent inhibitor of myeloproliferative disorders and cancer cells with constitutive activation of the Bcr-Abl kinase domain. Inhibition of this kinase leads to cell cycle arrest, apoptosis, and suppression of tumor growth in mice.

Propriétés chimiques

• Masse moléculaire: 489.47 g/mol
• Formule: C₂₆H₂₁F₂N₅O₃
• Degré de pureté: Min. 95%